Anthony Barnes, Ph.D.
, M.B.A.
Dr. Anthony Barnes focuses on applied product development and business
development/marketing. Dr. Barnes started his career as a senior scientist
at the Upjohn Company where he focused on the physical and chemical
characterization of new drug compounds, the analysis of drug metabolism,
and the chemometric characterization of protein based drug candidates.
Dr. Barnes then joined Booz Allen and Hamilton as a consultant, specializing
in the pharmaceutical and analytical instrumentation industries. During
one engagement, Dr. Barnes worked with the government to apply neural
networks to estimate crop yields from satellite photography. He was
recruited from Booz to become Manager in Licensing and Acquisitions
at Abbott Laboratories, Diagnostics Division. He was promoted to Marketing
Manager for the IMx Immunoassay instrument system, where he managed
a product line with over $800 million dollars in annual sales. From
that position, Dr. Barnes joined Life scan as Director of Product
Development, where he managed a 120-person team focused on the development
of a new blood glucose monitor. He was also intimately involved with
research in the non-invasive measurement of blood glucose using multiple
spectroscopic and tomographic techniques. Dr. Barnes next became Program
Director for Infectious Disease Immunoassay and Nucleic Acid Diagnostics
for Ciba Corning/Chiron. During this time, Dr. Barnes worked closely
with Ciba Geigy/Novartis in Basel, Switzerland to define new analytical
technologies for the detection of genetic information from both DNA
and MRNA. Dr. Barnes then joined the consulting firm of PRTM, where
he was immediately assigned as Program Leader for three major drug
programs at Merck Pharmaceuticals (Vioxx, Agrastat, Crixivan). After
three years of working with senior management for Merck, Dr. Barnes
left Merck/PRTM, helped to raise money for, and join the board of
Directors of Cytimmune Sciences, a start up company using colloidal
metals to deliver cytokine based proteins as cancer drugs. During
this period, Dr. Barnes became an expert in the manufacture and characterization
of nanoparticles. He then helped restart Immunicon, a pre-IPO company
using paramagnetic ferrofluids to separate metastatic cells from the
blood of cancer patients. At Immunicon, Dr. Barnes was Vice President
of Commercial Operations. In this role, he helped to raise $35 mm
in capital over 2 years and helped create deals with Ortho Diagnostics/Johnson
and Johnson Development Corporation, Therakos and Molecular Probes,
Inc. Upon vesting, Dr. Barnes joined Barnhill Technologies, Inc.
Dr. Barnes earned an undergraduate degree with high
honors in chemistry and biology from Illinois State University. During
his undergraduate career, Tony was also an Academic All-American football
player and was a Bone Scholar and Rhodes Scholarship nominee. Dr.
Barnes holds a Ph.D. in analytical biochemistry with a focus on computer
based instrumentation design and chemometric analysis from the University
of Illinois at Champaign Urbana, during which he was a 4 year recipient
of an NSF fellowship, and an MBA with Honors from the University of
Chicago with a specialization in finance and marketing.